WO1994024556A1 - Tetrazolium-based cell bioassay of marine neurotoxins - Google Patents

Tetrazolium-based cell bioassay of marine neurotoxins Download PDF

Info

Publication number
WO1994024556A1
WO1994024556A1 PCT/US1994/003876 US9403876W WO9424556A1 WO 1994024556 A1 WO1994024556 A1 WO 1994024556A1 US 9403876 W US9403876 W US 9403876W WO 9424556 A1 WO9424556 A1 WO 9424556A1
Authority
WO
WIPO (PCT)
Prior art keywords
toxin
sodium channel
cells
bioassay
fluid sample
Prior art date
Application number
PCT/US1994/003876
Other languages
French (fr)
Inventor
Ronald L. Manger
Linda S. Leja
Sue Y. Lee
James M. Hungerford
Marleen M. Wekell
Original Assignee
The United States Of America, As Represented By The Secretary Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America, As Represented By The Secretary Of Health And Human Services filed Critical The United States Of America, As Represented By The Secretary Of Health And Human Services
Priority to AU65308/94A priority Critical patent/AU6530894A/en
Publication of WO1994024556A1 publication Critical patent/WO1994024556A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds

Definitions

  • the present invention relates to an assay for the detection of sodium channel-specific toxins, particularly marine toxins, based upon mitochondrial dehydrogenase activity in the presence of ouabain and veratridine. More specifically, the present invention concerns a cell bioassay that allows the detection of either sodium channel blocking agents, such as saxitoxin, or sodium channel enhancers like brevetoxin and ciguatoxin.
  • sodium channel blocking agents such as saxitoxin, or sodium channel enhancers like brevetoxin and ciguatoxin.
  • PGP Paralytic shellfish poisoning
  • NSP Neurotoxic shellfish poisoning
  • brevetoxins perturb normal membrane properties of excitable cells by activating sodium channels.
  • Ciguatoxins which accumulate in tropical fish, also exert their biological effects through activation of sodium channels.
  • Tetrodotoxin, saxitoxin and related toxins which block sodium channels antagonize this effect, essentially rescuing the cells in a dose dependent manner. This phenomenon provides the basis of a sensitive in vitro bioassay for these toxins. But evaluation of the Kogure assay requires the visual scoring of 200 or more cells per sample or well, a potentially time-consuming and operator-dependent task.
  • Jellett et al . used a microplate reader for automated determinations of absorbances of toxin-treated cells which were stained with crystal violet.
  • This assay exploits the difference in adherence to the culture well of cells treated only with ouabain/veratridine and PSP toxin-treated cells. The former cells exhibit diminished adherence to the culture well, associated with swelling and lysis, and thus are readily removed by rinsing, whereas the latter retain substrate adherence.
  • a simplified bioassay for detecting the above- described toxins would be very useful. It also would be desirable to have a bioassay for detecting other types of toxins, especially those marine toxins that are sodium channel activators like the brevetoxins and the ciguatoxins. Since the known tissue culture-based bioassays are limited to detection of sodium channel blocking agents, there is a real need for a tissue culture-based bioassay which can detect marine toxins which have sodium channel activating properties as well display sodium channel blocking activity.
  • Another object of the present invention is to provide a cell bioassay capable of detecting both sodium channel- blocking and sodium channel-activating marine toxins.
  • a further object of the present invention is to provide a simplified cell bioassay.
  • Yet another object of the present invention is to provide a kit for carrying out the improved cell bioassay.
  • a cell bioassay method for determining the presence in a fluid sample of a toxin having sodium channel-affecting activity which comprises the steps of: incubating a plurality of cultures of cells which are responsive in a dose-dependent manner to sodium channel- affecting toxins with (i) a medium comprising a solution of ouabain and veratridine and (ii) a portion of the fluid sample, each culture being incubated with a different concentration of the fluid sample; removing the medium and fluid sample from the cultures; incubating the cultures with a medium comprising an indicator which is acted upon by living cells to form a measurable product; measuring the amounts of product formed during the preceding step; and relating the amounts of product so formed during the indicator incubation step to a standard calibration curve to determine the presence of toxin in the sample.
  • the cells are mouse neuroblastoma cells of the cell line Neuro-2a (ATCC CCL 131).
  • the indicator is 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) , which is metabolized by living cells to yield formazan as the measurable product.
  • kits for use in the foregoing cell bioassay method which comprises, in packaged combination: a solution of about 0.5 iH ouabain and about 0.05 mM veratridine, a solution of MTT, and means for contacting the solutions with the fluid sample.
  • the kit also includes a quantity of cells, preferably Neuro-2a cells.
  • FIGURE 1 is a graph of absorbance as a function of cell number in the inventive bioassay.
  • FIGURE 2 is a graph of the effect of increasing concentration of pure saxitoxin upon MTT development in a bioassay of the present invention,
  • FIGURE 3 is a graph of PSP toxin activity in aqueous Dungeness crab extracts as determined by an inventive bioassay
  • FIGURE 4 is a graph of brevitoxin PbTx-1 cytotoxicity as measured by an inventive assay
  • FIGURE 5 is a graph of ciguatoxin activity in wrasse extracts, as determined by an assay within the present invention.
  • the cell bioassay according to the present invention represents a significant improvement over the known assay methods.
  • the inventive bioassay is simpler, faster and more sensitive than the standard mouse assay, and requires less sample than the mouse assay.
  • the instant bioassay can also be carried out more easily than other previously known methods, since it requires fewer steps and no intermediate washing or fixation steps.
  • a bioassay according to the invention has utility in determining the presence, not only of marine toxins, but also of any other sodium channel-affecting toxins.
  • sodium channel-affecting activity denotes both sodium channel-blocking activity and sodium channel-enhancing activity
  • Exemplary toxins whose presence can be determined by use of bioassays within the invention include: carbamate toxins such as saxitoxin (STX) , neosaxitoxin (NEO) , gonyautoxins (GTX-I, GTX-II, GTX-III, GTX-IV) ; other members of the saxitoxin, neosaxitoxin and gonyautoxin families such as decarbamoyl (dc) toxins, including dc-STX, dc-NEO, dc-GTX-I, etc.; N- sulfocarbamoyl toxins such as toxins B-l, B-2, C-l, C-2, C-3 and C-4; tetrodotoxins; other PSP-producing toxins; brevetoxins such as PbTx-1, PbTx-2, PbTx-3, PbTx-5, PbTx- 6, PbTx-7, P
  • a bioassay within the present invention is effective in determining the presence of toxins having sodium channel-activating (or enhancing) activity, as well as sodium channel-blocking activity.
  • the inventive bioassay thus has additional utility as a diagnostic tool for determining either blocking or enhancing activity at the level of the sodium channel.
  • cytotoxicity in the presence of ouabain/veratridine (“cell rescue") is indicative of a sodium channel blocking toxin, such as saxitoxin or tetrodotoxin; enhancement of cytotoxicity in the presence of ouabain/veratridine is indicative of a potent sodium channel enhancer, such as a brevetoxin or ciguatoxin; while ouabain/veratridine-independent cytotoxicity suggests the presence of a toxin other than a sodium channel-affecting toxin, such as a diarrhetic shellfish poisoning (DSP) toxin, e.g., okadaic acid.
  • DSP diarrhetic shellfish poisoning
  • the cell cultures employed according to the inventive bioassay are responsive in a dose-dependent manner to sodium channel-affecting toxins.
  • the dose-dependent response of the cells occurs in the context of prior exposure to ouabain/veratridine.
  • the cells should be readily cultured, and should begin to show such a response within a reasonable time, such as about 4 to 18 hours, in the case of sodium channel-activating toxins, or about 24 to 48 hours in the case of sodium channel- blocking toxins.
  • Preferred cells include mouse neuroblastoma cells of the cell line Neuro-2a (ATCC CCL 131) .
  • the cells must also be responsive to the selected indicator.
  • the indicator employed in a bioassay within the instant invention distinguishes active, living cells from dead cells, and is a substrate for mitochondrial dehydrogenase. Living cells thus act upon the indicator to produce a measurable product, while dead cells do not act upon the indicator to produce a measurable product.
  • a particularly preferred indicator is MTT (3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) .
  • Other tetrazolium salts such as XTT, methylene blue and similar salts can also be used.
  • MTT colori etric test of cellular metabolism enables simplification of the bioassay method with respect to the known methods.
  • the MTT test is a rapid, versatile, quantitative, and simple technique to assess cell proliferation and cytotoxicity based upon the metabolism of MTT by mitochondrial dehydrogenase activity in viable cells. See Moss an, J. JBUDUJIO. Meth . 65: 55-63 (1983), the contents of which are hereby incorporated by reference.
  • MTT is metabolized only in living cells, whose mitochondria cleave its tetrazolium ring to produce a blue colored product (formazan) . The presence of for azan can be detected visually or spectrophotometrically and directly related to the number of living cells.
  • the presence of toxins in the fluid sample is determined from the effect of the fluid sample on cell viability, as evidenced by the level of cell metabolism of MTT and resultant formazan production.
  • Increased formazan production upon contact with increasing concentrations of toxin from the fluid sample indicates cell rescue, and hence the presence of sodium channel- blocking toxins.
  • Decreased formazan production indicates the presence of sodium channel- activating toxins.
  • MTT MTT
  • XTT 2,3-bis(2- methoxy-4-nitro-5-sulfophenyl) -2H-tetrazolium-5- carboxanilide inner salt
  • the inventive cell bioassay offers the advantage of significantly improved sensitivity in comparison to the standard mouse bioassay.
  • the animal assay can detect saxitoxin to a lower limit of 40 ⁇ g/100 g tissue See Hungerford et al . , 7 HANDBOOK OF NATURAL TOXINS, 416-73, Marcel Dekkar, Inc. (New York 1992) .
  • the cell bioassay according to the present invention can routinely detect purified saxitoxin at a level of 0.1 ng/10 ⁇ l, which is the equivalent of 2 ⁇ g/100 g tissue.
  • the observed limit of detection can be reduced to as low as 0.02 ng/10 ⁇ l (0.4 ⁇ g/100 g) .
  • This sensitivity is comparable to that obtained by Jellett et al . , supra .
  • the inventive cell assay also shows excellent correlation with the results obtained with the standard mouse bioassay for saxitoxin.
  • the instant cell bioassay is more sensitive to the presence of brevetoxins and ciguatoxins than the mouse bioassay.
  • the LD JO for brevetoxins in mice is 0.01 mg/20 g animal, i.p. injection. See Hungerford et al . , supra .
  • a significant advantage of the inventive cell bioassay is the rapidity of the method for the detection of sodium channel-activating toxins, such as brevetoxins and ciguatoxins, in comparison to the mouse bioassay.
  • Mouse bioassays for brevetoxins and ciguatoxins involve long observation periods, ranging from several hours to 24 hours. See Hungerford et al . , supra .
  • the bioassay according to the invention typically can be effected within 4 to 6 hours of exposure to these toxins, with subsequent processing and development time taking only about 30 minutes.
  • the inventive method typically requires on the order of 24-48 hours for the determination of sodium channel blocking agents such as saxitoxin, such times are also typical of known cell-based assays. Particularly when the rapidity of the mouse bioassay is not required, however, such as in the analysis of embargoed shellfish or in research applications where small aliquots of isolates must be tested, the instant invention offers clear advantages as described above.
  • kits can be provided for carrying out the inventive bioassay method.
  • the kits include the solutions utilized in the method of the invention, with all constituents in appropriate containers (vials, syringes, etc. ) in predetermined proportions and amounts.
  • the kits also include means for contacting the solutions with the fluid sample, such as multi-well plates.
  • the kits in addition preferably include an appropriate solvent for formazan, such as DMSO, and at least one calibration curve for a toxin having sodium channel- affecting activity.
  • Cell cultures employed in the bioassay can also be provided with the kits according to - lo ⁇
  • MTT The metabolism of MTT has been reported to be minimal in some cell cultures. See, e .g. , Carmichael et al . , Cancer Res . 47: 936-42 (1987); Alley et al . , loc. cit . 48: 589-601 (1988)). As shown below, the Neuro-2a cell line has been determined to be capable of effectively metabolizing MTT for the purposes of the inventive bioassay method.
  • Mouse neuroblastoma cells Neuro-2a (ATCC, CCL 131) were grown and maintained in RPMI 1640 (Sigma) containing 10% fetal bovine serum (Gibco) , glutamine (2 mM) (Sigma) , and sodium pyruvate (1 mM) (Sigma) . Streptomycin and penicillin (Sigma) were also added at 50 ⁇ g and 50 units per ml, respectively, to form a growth medium (hereinafter "complete growth medium”) . Cultures were maintained in an incubator at 37°C with a humidified 5% C0 2 :95% air atmosphere.
  • Example 2 Saxitoxin cell bioassay Purified saxitoxin, obtained from Calbiochem, was diluted in phosphate-buffered saline (PBS), pH 7.4 and maintained as a frozen stock at -20°C. Prior to assay the saxitoxin stock was diluted to the appropriate concentration with complete growth medium. Cultures were prepared for bioassay as described by Jellett et al., supra , with the modifications described below. Cells were harvested with a trypsin EDTA solution (0.5%/0.2%) (Sigma) in PBS and seeded into 96-well plates (CoStar) at a density of 5 x 10 5 cells/ml in 200 ⁇ l complete growth medium per well. The cultures were incubated at 37°C under a 5% C0 2 atmosphere for approximately 24 hours before proceeding further.
  • PBS phosphate-buffered saline
  • CoStar 96-well plates
  • the culture wells received 10 ⁇ l of sample and 10 ⁇ l additions of aqueous stocks of 10 mM ouabain (Sigma) and l mM veratridine (Sigma), pH 2. Each sample concentration was tested in replicate (3 to 5 wells) . A minimum of 15 wells per plate were processed as ouabain/veratridine-treated controls (no sample addition, 0.5 mM ouabain, 0.05 mM veratridine), and a minimum of 5 wells served as untreated controls (without ouabain/veratridine and without sample) . Control wells received added culture medium to make up for volume differences of sample and ouabain/veratridine (up to 30 ⁇ l per well) . The cultures were then incubated for 24-48 hours.
  • MTT (3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (Sigma)), was prepared as a 5 mg/ml stock solution in PBS, pH 7.4, and stored at 4°C until use. Following incubation with the samples, the overlaying medium was removed from each of the cultures, and, without a wash step, 60 ⁇ l of a 1:6 dilution of the MTT stock in complete growth medium was added to each well. The cultures were then incubated for approximately 15 minutes at 37°C, or until a suitable deposit of reduced dark formazan deposit was observed in control wells (occasionally up to 30-45 minutes) .
  • the incubation medium was then removed, and without, an intermediate rinsing step, 100 ⁇ l of DMSO was added to each well.
  • the plates were immediately read on a Dynatech MR-5000 automated multiwell scanning spectrophotometer using a test wavelength of 570 n and a reference wavelength of 630 nm.
  • saxitoxin was detected at a level of 0.1 ng/10 ⁇ l addition using an approximate MTT development time of 15 minutes (see Figure 2a) . Assay sensitivity could occasionally be enhanced by increasing MTT development time to approximately 45 minutes, with a resultant detection limit of about 0.02 ng/10 ⁇ l addition (see Figure 2b) . However, with added MTT development time the assay tended to plateau at higher concentrations of saxitoxin. Assay sensitivities were comparable to that reported by Jellett et al . , supra. In the absence of ouabain/veratridine treatment, saxitoxin at the concentrations tested had no measurable effect.
  • the cell bioassay detected mean values (with standard deviations) of 124 ⁇ 44 ⁇ g/100 g in the positive extract (mouse bioassay) .
  • the extract that was PSP-negative by mouse bioassay had a mean value of 33 ⁇ 2 ⁇ g/100 g tissue in the inventive bioassay.
  • This level of saxitoxin is below the standard detection limit of the animal test (40 ⁇ g/100 g) .
  • the dose response curves tended to plateau with increasing concentrations of extract (dilutions of less than 1:4), suggesting a competing or potentially interfering cytotoxic component.
  • Example 4 Brevetoxin cell bioassay
  • Brevetoxins PbTx-1 and PbTx-3 were dissolved in methanol to form a stock. Prior to assay brevetoxin stock solution was diluted 1:100 in complete growth medium, from which serial dilutions in complete growth medium were then made. The cultures were prepared for bioassay as described in Example 2, except that 10 ⁇ l samples were added to replicate culture wells in both the presence and absence of ouabain and veratridine. The cultures were then incubated 2-22 hours.
  • the cell bioassay was performed essentially as described in Example 2 for saxitoxin. However, instead of measuring cell rescue, an assessment of toxin-enhanced cytotoxicity in the presence of ouabain/veratridine was performed. The effect of increasing concentrations, and time of exposure, of brevetoxin PbTx-1 in the cell bioassay are shown in Figures 4a and b. In the figures, brevetoxin cytotoxicity was assayed at 2 hours (O) . 4 hours (•) , 6 hours ( ⁇ ) and 18 hours (A) . Values represent the mean of four replicates.
  • a ciguatoxic fish extract (methanol fraction) prepared from wrasse, Cheilinus rhodochrous, was generously provided by Dr. Yoshitsugi Hokama, University of Hawaii. A stock solution of this material was prepared in the same manner as the brevetoxins in Example 4.

Abstract

An inventive bioassay method can be used to determine the presence in a fluid sample of a toxin having sodium channel-affecting activity. The method includes the steps of incubating a plurality of cultures of cells which are responsive in a dose-dependent manner to sodium channel-affecting toxins with (i) a medium comprising a solution of ouabain and veratridine and (ii) a portion of the fluid sample, each culture being incubated with a different concentration of the fluid sample; removing the medium and fluid sample from the cultures; incubating the cultures with a medium comprising an indicator which is acted upon by living cells to form a measurable product; measuring the amounts of product formed during the preceding step; and relating the amounts of product measured to a standard calibration curve to determine the presence of the toxin in the sample. The method is readily embodied in kit form and is amenable to automation.

Description

TETRAZOLIUM-BASED CELL BIOASSAY OF MARINE NEϋROTOXINS
Background of the Invention The present invention relates to an assay for the detection of sodium channel-specific toxins, particularly marine toxins, based upon mitochondrial dehydrogenase activity in the presence of ouabain and veratridine. More specifically, the present invention concerns a cell bioassay that allows the detection of either sodium channel blocking agents, such as saxitoxin, or sodium channel enhancers like brevetoxin and ciguatoxin.
Commercially important species of shellfish and finfish are known to occasionally present a serious health risk to consumers due to the presence of accumulated marine toxins. A significant number of these marine toxins exert their effects by interaction with voltage sensitive sodium channels in excitable membranes. Paralytic shellfish poisoning (PSP) is attributed to the ingestion of molluscan shellfish that have accumulated saxitoxins or related compounds from toxic dinoflagellate blooms. The saxitoxins selectively block ion transport at the sodium channel. Neurotoxic shellfish poisoning (NSP) is caused by the ingestion of shellfish that have sequestered brevetoxins from the dinoflagellate associated with Florida's red tide. In contrast to the action of saxitoxin, brevetoxins perturb normal membrane properties of excitable cells by activating sodium channels. Ciguatoxins, which accumulate in tropical fish, also exert their biological effects through activation of sodium channels.
Monitoring programs for marine toxins have depended in large part upon mouse bioassays. Although mouse bioassays have for many years provided a fairly reliable assessment of risk, there is mounting pressure to develop alternative assays to reduce the reliance on animal testing. To this end Kogure et al . developed a tissue culture assay for tetrodotoxin, saxitoxin, and related toxins. See Kogure et al . , Toxicon 26 (2): 191-97 (1988) . In the Kogure assay, a mouse neuroblasto a cell line (Neuro-2a) is treated with a fixed concentration of the sodium channel activator veratridine in the presence of ouabain, an inhibitor of Na+/K+ ATPase. The combined effect of these agents is an enhanced sodium influx, leading to altered cell morphology, a subsequent decrease in cell viability and ultimate cell lysis. Tetrodotoxin, saxitoxin and related toxins which block sodium channels antagonize this effect, essentially rescuing the cells in a dose dependent manner. This phenomenon provides the basis of a sensitive in vitro bioassay for these toxins. But evaluation of the Kogure assay requires the visual scoring of 200 or more cells per sample or well, a potentially time-consuming and operator-dependent task.
Scoring of this assay was improved by the modifications described by Jellett et al . , Toxicon 30 (10): 1143-56 (1992), the contents of which are hereby incorporated by reference. Jellett et al . used a microplate reader for automated determinations of absorbances of toxin-treated cells which were stained with crystal violet. This assay exploits the difference in adherence to the culture well of cells treated only with ouabain/veratridine and PSP toxin-treated cells. The former cells exhibit diminished adherence to the culture well, associated with swelling and lysis, and thus are readily removed by rinsing, whereas the latter retain substrate adherence. Thus, cells affected only by ouabain/veratridine lose adherence and are removed during rinsing, while cells inoculated with the toxin, and thus protected from the effects of ouabain/veratridine, remain in the well. In the Jellett assay, wells containing Neuro-2a cells are inoculated with toxin and then with ouabain/veratridine, incubated, and subsequently rinsed. After rinsing, the wells are fixed and subsequently stained with crystal violet. The processed plates are then dried, followed by digestion of the stained cells in acetic acid. Finally, the plates are read for absorbance of crystal violet in each well, with the absorbance being directly related to the amount of PSP toxin originally present. These modifications notably improve the application of the cell bioassay developed by Kogure et al . But the numerous steps involving mechanical removal of cells and treatment of the plates may be subject to operator variability.
Thus, a simplified bioassay for detecting the above- described toxins would be very useful. It also would be desirable to have a bioassay for detecting other types of toxins, especially those marine toxins that are sodium channel activators like the brevetoxins and the ciguatoxins. Since the known tissue culture-based bioassays are limited to detection of sodium channel blocking agents, there is a real need for a tissue culture-based bioassay which can detect marine toxins which have sodium channel activating properties as well display sodium channel blocking activity.
.ςιπnτna y of the Invention Accordingly, it is an object of the present invention to provide an improved cell bioassay for sodium channel- affecting toxins, particularly marine toxins.
Another object of the present invention is to provide a cell bioassay capable of detecting both sodium channel- blocking and sodium channel-activating marine toxins. A further object of the present invention is to provide a simplified cell bioassay.
Yet another object of the present invention is to provide a kit for carrying out the improved cell bioassay.
In accomplishing the foregoing objectives, there has been provided, in accordance with one aspect of the present invention, a cell bioassay method for determining the presence in a fluid sample of a toxin having sodium channel-affecting activity which comprises the steps of: incubating a plurality of cultures of cells which are responsive in a dose-dependent manner to sodium channel- affecting toxins with (i) a medium comprising a solution of ouabain and veratridine and (ii) a portion of the fluid sample, each culture being incubated with a different concentration of the fluid sample; removing the medium and fluid sample from the cultures; incubating the cultures with a medium comprising an indicator which is acted upon by living cells to form a measurable product; measuring the amounts of product formed during the preceding step; and relating the amounts of product so formed during the indicator incubation step to a standard calibration curve to determine the presence of toxin in the sample. In a preferred embodiment, the cells are mouse neuroblastoma cells of the cell line Neuro-2a (ATCC CCL 131). Preferably, the indicator is 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) , which is metabolized by living cells to yield formazan as the measurable product.
In accordance with another aspect of the present invention there is provided a kit for use in the foregoing cell bioassay method which comprises, in packaged combination: a solution of about 0.5 iH ouabain and about 0.05 mM veratridine, a solution of MTT, and means for contacting the solutions with the fluid sample. In a preferred embodiment, the kit also includes a quantity of cells, preferably Neuro-2a cells.
Other objects, features and advantages of the present invention will become apparent to those skilled in the art from the following detailed description. It is to be understood, however, that the detailed description and specific examples, while indicating preferred embodiments of the present invention, are given by way of illustration and not limitation. Many changes and modifications within the scope of the present invention may be made without departing from the spirit thereof, and the invention includes all such modifications. Brief Description of the Drawing The present invention is more readily understood by reference to the accompanying drawing by which
FIGURE 1 is a graph of absorbance as a function of cell number in the inventive bioassay. FIGURE 2 is a graph of the effect of increasing concentration of pure saxitoxin upon MTT development in a bioassay of the present invention,
FIGURE 3 is a graph of PSP toxin activity in aqueous Dungeness crab extracts as determined by an inventive bioassay,
FIGURE 4 is a graph of brevitoxin PbTx-1 cytotoxicity as measured by an inventive assay, and
FIGURE 5 is a graph of ciguatoxin activity in wrasse extracts, as determined by an assay within the present invention.
Detailed Description of Preferred Embodiments
The cell bioassay according to the present invention represents a significant improvement over the known assay methods. The inventive bioassay is simpler, faster and more sensitive than the standard mouse assay, and requires less sample than the mouse assay. Furthermore, the instant bioassay can also be carried out more easily than other previously known methods, since it requires fewer steps and no intermediate washing or fixation steps.
It is contemplated that a bioassay according to the invention has utility in determining the presence, not only of marine toxins, but also of any other sodium channel-affecting toxins. (As used herein, the term "sodium channel-affecting activity" denotes both sodium channel-blocking activity and sodium channel-enhancing activity) . Exemplary toxins whose presence can be determined by use of bioassays within the invention include: carbamate toxins such as saxitoxin (STX) , neosaxitoxin (NEO) , gonyautoxins (GTX-I, GTX-II, GTX-III, GTX-IV) ; other members of the saxitoxin, neosaxitoxin and gonyautoxin families such as decarbamoyl (dc) toxins, including dc-STX, dc-NEO, dc-GTX-I, etc.; N- sulfocarbamoyl toxins such as toxins B-l, B-2, C-l, C-2, C-3 and C-4; tetrodotoxins; other PSP-producing toxins; brevetoxins such as PbTx-1, PbTx-2, PbTx-3, PbTx-5, PbTx- 6, PbTx-7, PbTx-8, etc.; ciguatoxins such as CTX-1, CTX- 2, CTX-3, etc.; other NSP-producing toxins; and the like (see J. Hungerford et al . , "Analytical Methods for Marine Toxins" , 7 Food Poisoning: Handbook of Natural Toxins , ch. 16, pp. 415-473 (ed. A. Tu, Marcel Dekker Inc, New York, New York 1992).
Unlike conventional assay methods, a bioassay within the present invention is effective in determining the presence of toxins having sodium channel-activating (or enhancing) activity, as well as sodium channel-blocking activity. The inventive bioassay thus has additional utility as a diagnostic tool for determining either blocking or enhancing activity at the level of the sodium channel. Specifically, reduction of cytotoxicity in the presence of ouabain/veratridine ("cell rescue") is indicative of a sodium channel blocking toxin, such as saxitoxin or tetrodotoxin; enhancement of cytotoxicity in the presence of ouabain/veratridine is indicative of a potent sodium channel enhancer, such as a brevetoxin or ciguatoxin; while ouabain/veratridine-independent cytotoxicity suggests the presence of a toxin other than a sodium channel-affecting toxin, such as a diarrhetic shellfish poisoning (DSP) toxin, e.g., okadaic acid.
The cell cultures employed according to the inventive bioassay are responsive in a dose-dependent manner to sodium channel-affecting toxins. The dose-dependent response of the cells occurs in the context of prior exposure to ouabain/veratridine. The cells should be readily cultured, and should begin to show such a response within a reasonable time, such as about 4 to 18 hours, in the case of sodium channel-activating toxins, or about 24 to 48 hours in the case of sodium channel- blocking toxins. Preferred cells include mouse neuroblastoma cells of the cell line Neuro-2a (ATCC CCL 131) . The cells must also be responsive to the selected indicator.
The indicator employed in a bioassay within the instant invention distinguishes active, living cells from dead cells, and is a substrate for mitochondrial dehydrogenase. Living cells thus act upon the indicator to produce a measurable product, while dead cells do not act upon the indicator to produce a measurable product. A particularly preferred indicator is MTT (3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) . Other tetrazolium salts such as XTT, methylene blue and similar salts can also be used.
Incorporation of the MTT colori etric test of cellular metabolism enables simplification of the bioassay method with respect to the known methods. The MTT test is a rapid, versatile, quantitative, and simple technique to assess cell proliferation and cytotoxicity based upon the metabolism of MTT by mitochondrial dehydrogenase activity in viable cells. See Moss an, J. JBUDUJIO. Meth . 65: 55-63 (1983), the contents of which are hereby incorporated by reference. MTT is metabolized only in living cells, whose mitochondria cleave its tetrazolium ring to produce a blue colored product (formazan) . The presence of for azan can be detected visually or spectrophotometrically and directly related to the number of living cells.
Thus, the presence of toxins in the fluid sample is determined from the effect of the fluid sample on cell viability, as evidenced by the level of cell metabolism of MTT and resultant formazan production. Increased formazan production upon contact with increasing concentrations of toxin from the fluid sample indicates cell rescue, and hence the presence of sodium channel- blocking toxins. Decreased formazan production, on the other hand, indicates the presence of sodium channel- activating toxins.
Besides MTT, it is contemplated that other indicators which are similarly capable of distinguishing living from dead cells can be employed in bioassays within the instant invention. One such indicator is 2,3-bis(2- methoxy-4-nitro-5-sulfophenyl) -2H-tetrazolium-5- carboxanilide inner salt (XTT) (Sigma #X4251) . See Parsons et al . , J. Heterocyclic Chem . 25: 911 (1988); Scudievo et al . , Cancer Res . 48: 4827 (1988).
As noted, no intermediate washing or fixing steps are required in the inventive bioassay method. The cultured cells need only be contacted sequentially with the various fluids, the last being a solvent for formazan which facilitates the spectrophotometric measurement of the amount of formazan produced by the cell culture.
In addition to simplicity, the inventive cell bioassay offers the advantage of significantly improved sensitivity in comparison to the standard mouse bioassay. The animal assay can detect saxitoxin to a lower limit of 40 μg/100 g tissue See Hungerford et al . , 7 HANDBOOK OF NATURAL TOXINS, 416-73, Marcel Dekkar, Inc. (New York 1992) . In contrast, the cell bioassay according to the present invention can routinely detect purified saxitoxin at a level of 0.1 ng/10 μl, which is the equivalent of 2 μg/100 g tissue. Under some conditions, with extended MTT development time, the observed limit of detection can be reduced to as low as 0.02 ng/10 μl (0.4 μg/100 g) . This sensitivity is comparable to that obtained by Jellett et al . , supra . The inventive cell assay also shows excellent correlation with the results obtained with the standard mouse bioassay for saxitoxin. In a similar manner, the instant cell bioassay is more sensitive to the presence of brevetoxins and ciguatoxins than the mouse bioassay. The LDJO for brevetoxins in mice is 0.01 mg/20 g animal, i.p. injection. See Hungerford et al . , supra . This correlates to 0.1 mg/100 g tissue extract and is the equivalent of a 1 ng/10 μl sample in the instant cell bioassay. In the examples given below, brevetoxins are detected at levels of 0.25 ng/10 μl (Example 4; also Figures 4a-b) . Ciguatoxic extracts (utilized in Example 5, below) produced death in 20 g mice following injection of 50 mg in 1 ml within 2.5 hours (estimated toxicity score of about 0.3 mouse units per mg; bioassay results and sample generously provided by Dr. Yoshitsugi Hokama, University of Hawaii) , and contained the estimated equivalent of 100 ng ciguatoxin (CTX-1) . The sodium channel activity of this extract was readily detected in the instant cell bioassay at levels of less than 10"4 mouse units, corresponding to approximately 1 pg of CTX-1.
A significant advantage of the inventive cell bioassay is the rapidity of the method for the detection of sodium channel-activating toxins, such as brevetoxins and ciguatoxins, in comparison to the mouse bioassay. Mouse bioassays for brevetoxins and ciguatoxins involve long observation periods, ranging from several hours to 24 hours. See Hungerford et al . , supra . The bioassay according to the invention typically can be effected within 4 to 6 hours of exposure to these toxins, with subsequent processing and development time taking only about 30 minutes.
Although the inventive method typically requires on the order of 24-48 hours for the determination of sodium channel blocking agents such as saxitoxin, such times are also typical of known cell-based assays. Particularly when the rapidity of the mouse bioassay is not required, however, such as in the analysis of embargoed shellfish or in research applications where small aliquots of isolates must be tested, the instant invention offers clear advantages as described above.
For convenience, kits can be provided for carrying out the inventive bioassay method. The kits include the solutions utilized in the method of the invention, with all constituents in appropriate containers (vials, syringes, etc. ) in predetermined proportions and amounts. The kits also include means for contacting the solutions with the fluid sample, such as multi-well plates. The kits in addition preferably include an appropriate solvent for formazan, such as DMSO, and at least one calibration curve for a toxin having sodium channel- affecting activity. Cell cultures employed in the bioassay can also be provided with the kits according to - lo ¬
an embodiment of the invention. In some instances, such as the preferred embodiments using Neuro-2a cells, it may be necessary to provide the cells and the remaining components of the kits separately, maintained at different temperatures. In another embodiment, the multiwell plates can be "pre-seeded" with the cell culture in a manner known to those skilled in the art, then shipped for overnight delivery to the user with the other kit components. The inventive bioassay also is well-suited to automation, making possible the screening of large numbers of samples with minimal operator intervention. This provides for a convenient biological assay that can be accomplished within one day. The present invention is described further by reference to the following, non-limiting examples. Example 1 Cell culture
The metabolism of MTT has been reported to be minimal in some cell cultures. See, e .g. , Carmichael et al . , Cancer Res . 47: 936-42 (1987); Alley et al . , loc. cit . 48: 589-601 (1988)). As shown below, the Neuro-2a cell line has been determined to be capable of effectively metabolizing MTT for the purposes of the inventive bioassay method. Mouse neuroblastoma cells Neuro-2a (ATCC, CCL 131) were grown and maintained in RPMI 1640 (Sigma) containing 10% fetal bovine serum (Gibco) , glutamine (2 mM) (Sigma) , and sodium pyruvate (1 mM) (Sigma) . Streptomycin and penicillin (Sigma) were also added at 50 μg and 50 units per ml, respectively, to form a growth medium (hereinafter "complete growth medium") . Cultures were maintained in an incubator at 37°C with a humidified 5% C02:95% air atmosphere.
The ability of Neuro-2a cells to metabolize this tetrazolium salt as an index of viable cell number is show in Figure 1. Cells were plated at the density indicated on the x-axis and allowed to recover for 24 hours at 37°C prior to incubation with MTT for 15 minutes. Following solubilization in an appropriate solvent (here, DMSO) , the amount of blue formazan product was then measured at 570 n . Values shown in Figure 1 represent the mean of 6 replicates, with the error bars indicating ± SD (standard deviation) . Absorbance was proportional to initial cell inoculum and exhibited excellent reproducibility between replicate wells. Example 2 Saxitoxin cell bioassay Purified saxitoxin, obtained from Calbiochem, was diluted in phosphate-buffered saline (PBS), pH 7.4 and maintained as a frozen stock at -20°C. Prior to assay the saxitoxin stock was diluted to the appropriate concentration with complete growth medium. Cultures were prepared for bioassay as described by Jellett et al., supra , with the modifications described below. Cells were harvested with a trypsin EDTA solution (0.5%/0.2%) (Sigma) in PBS and seeded into 96-well plates (CoStar) at a density of 5 x 105 cells/ml in 200 μl complete growth medium per well. The cultures were incubated at 37°C under a 5% C02 atmosphere for approximately 24 hours before proceeding further.
The culture wells received 10 μl of sample and 10 μl additions of aqueous stocks of 10 mM ouabain (Sigma) and l mM veratridine (Sigma), pH 2. Each sample concentration was tested in replicate (3 to 5 wells) . A minimum of 15 wells per plate were processed as ouabain/veratridine-treated controls (no sample addition, 0.5 mM ouabain, 0.05 mM veratridine), and a minimum of 5 wells served as untreated controls (without ouabain/veratridine and without sample) . Control wells received added culture medium to make up for volume differences of sample and ouabain/veratridine (up to 30 μl per well) . The cultures were then incubated for 24-48 hours.
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (Sigma)), was prepared as a 5 mg/ml stock solution in PBS, pH 7.4, and stored at 4°C until use. Following incubation with the samples, the overlaying medium was removed from each of the cultures, and, without a wash step, 60 μl of a 1:6 dilution of the MTT stock in complete growth medium was added to each well. The cultures were then incubated for approximately 15 minutes at 37°C, or until a suitable deposit of reduced dark formazan deposit was observed in control wells (occasionally up to 30-45 minutes) . The incubation medium was then removed, and without, an intermediate rinsing step, 100 μl of DMSO was added to each well. The plates were immediately read on a Dynatech MR-5000 automated multiwell scanning spectrophotometer using a test wavelength of 570 n and a reference wavelength of 630 nm.
Morphological alteration and subsequent cell loss was observed in cells incubated with 0.5 mM ouabain and 0.05 mM veratridine. This effect was maximal between 24-48 h, in agreement with previous reports. See Kogure et al. and Jellett et al . , supra . Saxitoxin-dependent cell rescue was measured directly by alterations in MTT metabolism, as shown in Figure 2 (values represent the mean of 3-4 replicates) .
Purified saxitoxin was detected at a level of 0.1 ng/10 μl addition using an approximate MTT development time of 15 minutes (see Figure 2a) . Assay sensitivity could occasionally be enhanced by increasing MTT development time to approximately 45 minutes, with a resultant detection limit of about 0.02 ng/10 μl addition (see Figure 2b) . However, with added MTT development time the assay tended to plateau at higher concentrations of saxitoxin. Assay sensitivities were comparable to that reported by Jellett et al . , supra. In the absence of ouabain/veratridine treatment, saxitoxin at the concentrations tested had no measurable effect. (For the purpose of comparison, 0.1 ng/10 μl and 0.02 ng/10 μl saxitoxin are equivalent to shellfish extracts of 2 μg/100 g tissue and 0.4 μg/100 g tissue, respectively.) Example 3 Cell bioassay of crab viscera
To test the applicability of the inventive bioassay for the detection of naturally incurred PSP in samples, acid extracts of viscera from Dungeness crab. Cancer magister, were examined. The crab viscera extracts were generously made available by Cheryl Eklund and James Bryant, FDA, Bothell, Washington. Toxicity levels were determined previously by mouse bioassay of the entire visceral portions of the crabs. See OFFICIAL METHODS OF ANALYSIS OF THE AOAC, par. 959.08, 881 (K. Helrich, ed. 1990) .
Two extracts exhibiting positive and negative PSP activity by the AOAC mouse bioassay (122 μg/100 g and none detected/100 g respectively) were tested at various dilutions in the cell bioassay. Cultures were prepared for bioassay, incubated and assayed as described in Example 2.
Levels of saxitoxin activity were calculated by comparing linear portions of the crab viscera dose response curves (dilutions of 1/32, 1/16, and 1/8) with a standard curve derived using pure saxitoxin, and multiplying interpolated toxin concentrations by the appropriate dilution factor. Results are set forth in Figure 3, in which (•) and (O) indicate extracts testing at 122 μg/100 g and no detectable activity using the standard mouse bioassay, respectively.
As calculated from the three highest dilutions, the cell bioassay detected mean values (with standard deviations) of 124 ±44 μg/100 g in the positive extract (mouse bioassay) . Interestingly, the extract that was PSP-negative by mouse bioassay had a mean value of 33±2 μg/100 g tissue in the inventive bioassay. This level of saxitoxin is below the standard detection limit of the animal test (40 μg/100 g) . The dose response curves tended to plateau with increasing concentrations of extract (dilutions of less than 1:4), suggesting a competing or potentially interfering cytotoxic component. Example 4 Brevetoxin cell bioassay
Brevetoxins PbTx-1 and PbTx-3 (Calbioche ) were dissolved in methanol to form a stock. Prior to assay brevetoxin stock solution was diluted 1:100 in complete growth medium, from which serial dilutions in complete growth medium were then made. The cultures were prepared for bioassay as described in Example 2, except that 10 μl samples were added to replicate culture wells in both the presence and absence of ouabain and veratridine. The cultures were then incubated 2-22 hours.
The cell bioassay was performed essentially as described in Example 2 for saxitoxin. However, instead of measuring cell rescue, an assessment of toxin-enhanced cytotoxicity in the presence of ouabain/veratridine was performed. The effect of increasing concentrations, and time of exposure, of brevetoxin PbTx-1 in the cell bioassay are shown in Figures 4a and b. In the figures, brevetoxin cytotoxicity was assayed at 2 hours (O) . 4 hours (•) , 6 hours (■) and 18 hours (A) . Values represent the mean of four replicates.
In the dose range explored, titratable cytotoxicity was observed as early as 4 hours (Figure 4a) and was essentially total at 18 hours. Brevetoxin in the absence of ouabain/veratridine was not cytotoxic even at the highest concentration and incubation time tested (10 ng/10 μl, 18 hours exposure) (Figure 4b) . PbTx-3 produced similar results as observed for PbTx-1 in the cell bioassay. Example 5 Ciguatoxin cell bioassay
A ciguatoxic fish extract (methanol fraction) , prepared from wrasse, Cheilinus rhodochrous, was generously provided by Dr. Yoshitsugi Hokama, University of Hawaii. A stock solution of this material was prepared in the same manner as the brevetoxins in Example 4.
Cultures were prepared for bioassay, incubated and assayed as described in Example 4. The extract was diluted and applied to the cells in the presence or absence of ouabain/veratridine. Within 6 hours the sample produced significant dose-dependent cytotoxicity only in cells treated with ouabain/veratridine (data obtained at 6 hours (•) and 22 hours (O) ) , as shown in Figure 5 (values represent the mean of four replicates) . Even after prolonged exposures of up to 22 hours the ciguatoxic extract was not cytotoxic in the inventive cell bioassay in the absence of ouabain/veratridine treatment (data obtained at 22 hours (Δ)) .
Example 6 Kit
The following components are combined in packaged form (liquid solutions in appropriate containers) : ouabain/veratridine solution (0.5 mM/0.05 mM) 5-25 ml
MTT solution
(5 mg/ml in PBS, pH 7.4) 5-25 ml 96-well plate (1)

Claims

WHAT IS CLAIMED IS:
1. A cell bioassay method for determining the presence in a fluid sample of a toxin having sodium channel-affecting activity which comprises the steps of
(a) incubating a plurality of cultures of cells which are responsive in a dose-dependent manner to sodium channel-affecting toxins with (i) a medium comprising a solution of ouabain and veratridine and (ii) a portion of said fluid sample, each said culture being incubated with a different concentration of said fluid sample,
(b) removing said medium and fluid sample from said cultures ,
(c) incubating said cultures with a medium comprising an indicator which is acted upon by living cells to form a measurable product,
(d) measuring the amounts of product formed during step (c) , and
(e) relating the amounts of product measured in step (d) to a standard calibration curve to determine the presence of said toxin in said sample.
2. A method as claimed in claim 1, wherein said cells are mouse neuroblastoma cells of the cell line Neuro-2a (ATCC CCL 131) .
3. A method as claimed in claim 1, wherein said indicator is 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and said measurable product is formazan.
4. A method as claimed in claim 1, wherein in step (a) said cultures are incubated with about 0.5mM ouabain and about 0.05 mM veratridine.
5. A method as claimed in claim 1, wherein said toxin has sodium channel blocking activity.
6. A method as claimed in claim 5, wherein step (a) is carried out for about 24 to 48 hours.
7. A method as claimed in claim 5, wherein said toxin is a paralytic shellfish poisoning (PSP) toxin.
8. A method as claimed in claim 7, wherein said toxin is a saxitoxin, a neosaxitoxin or a gonyautoxin.
9. A method as claimed in claim 5, wherein said toxin is tetrodotoxin.
10. A method as claimed in claim 1, wherein said toxin has sodium channel-activating activity.
11. A method as claimed in claim 10, wherein step (a) is carried out for about 2 to 22 hours.
12. A method as claimed in claim 11, wherein step (a) is carried out for about 4 to 6 hours.
13. A method as claimed in claim 10, wherein said toxin is an neurotoxic shellfish poisoning (NSP) toxin.
14. A method as claimed in claim 13, wherein said toxin is a brevetoxin.
15. A method as claimed in claim 10, wherein said toxin is a ciguatoxin.
16. A method as claimed in claim 1, wherein step (d) is effected by colorimetric means.
17. A kit for use in a cell bioassay method for determining the presence in a fluid sample of a toxin having sodium channel-affecting activity which comprises, in packaged combination,
(a) a solution of about 0.5 mM ouabain and about 0.05 mM veratridine,
(b) a solution of 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyl tetrazolium bromide (MTT) , and
(c) means for contacting said solutions with said fluid sample.
18. A kit as claimed in claim 17, further comprising a solvent for formazan.
19. A kit as claimed in claim 18, wherein said solvent is dimethyl sulfoxide (DMSO) .
20. A kit as claimed in claim 17, wherein said contacting means is a multiwell plate.
21. A kit as claimed in claim 17, further comprising at least one calibration curve for a toxin having sodium channel-affecting activity.
22. A kit as claimed in claim 17, further comprising a culture of Neuro-2a cells.
23. A method as claimed in claim 1, further comprising the step of relating the amounts of product measured in step (d) to a standard calibration curve to determine whether said sodium channel-affecting toxin is a sodium channel-blocking toxin or a sodium channel- activating toxin.
PCT/US1994/003876 1993-04-12 1994-04-12 Tetrazolium-based cell bioassay of marine neurotoxins WO1994024556A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU65308/94A AU6530894A (en) 1993-04-12 1994-04-12 Tetrazolium-based cell bioassay of marine neurotoxins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/045,067 US5420011A (en) 1993-04-12 1993-04-12 Cell bioassay for neurotoxins
US08/045,067 1993-04-12

Publications (1)

Publication Number Publication Date
WO1994024556A1 true WO1994024556A1 (en) 1994-10-27

Family

ID=21935830

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/003876 WO1994024556A1 (en) 1993-04-12 1994-04-12 Tetrazolium-based cell bioassay of marine neurotoxins

Country Status (3)

Country Link
US (3) US5420011A (en)
AU (1) AU6530894A (en)
WO (1) WO1994024556A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420011A (en) * 1993-04-12 1995-05-30 The United States Of America As Represented By The Department Of Health And Human Services Cell bioassay for neurotoxins
US5843696A (en) * 1995-11-01 1998-12-01 Wisconsin Alumni Research Foundation Bioassay for toxic substances activated by metabolic enzyme system
US6489119B1 (en) * 1996-03-29 2002-12-03 Elan Pharmaceuticals, Inc. Analgesic screening method and composition
EP0857972A1 (en) * 1997-01-24 1998-08-12 Tepual, S.A. Immunoassay for the detection and quantitation of toxins causing paralytic shellfish poisoning
WO1998040492A1 (en) * 1997-03-11 1998-09-17 Cambridge Genetics Limited Compositions and methods for elimination of unwanted cells
NZ526300A (en) * 2000-12-12 2004-12-24 Australian Inst Marine Science Detecting the presence of toxins (PSTs) in marine organisms by biochemical, physiological or chemical assays
US6770484B2 (en) 2001-11-29 2004-08-03 Dong C. Liang Using flame and graphite furnace atomic absorption spectrometry for analysis of sodium channel activity
US20030157586A1 (en) * 2002-02-21 2003-08-21 Martin Bonde Device and method for conducting cellular assays using multiple fluid flow
US7125676B2 (en) 2002-02-25 2006-10-24 Vanderbilt University Expression system for human brain-specific voltage-gated sodium channel, type 1
AU2003259289A1 (en) * 2002-07-30 2004-02-16 University Of Washington Apparatus and methods for binding molecules and cells
WO2007034521A1 (en) * 2005-09-26 2007-03-29 Universita' Degli Studi Di Bari Use of bone marrow stromal cells for the treatment of tendons and/or ligaments damages
US7422857B2 (en) * 2005-10-28 2008-09-09 University Of South Florida Detection of polyketide synthetase gene expression in Karenia brevis
RU2465592C1 (en) * 2011-06-06 2012-10-27 Федеральное государственное учреждение здравоохранения Волгоградский научно-исследовательский противочумный институт Роспотребнадзора METHOD FOR ASSESSING CYTOTOXICITY OF Burcholderia pseudomallei antigens in vitro
CN113607707B (en) * 2021-08-05 2024-03-12 国家食品安全风险评估中心 Ocean neurotoxin fluorescence rapid screening method based on sodium ion channel Nav1.1

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118624A (en) * 1989-02-27 1992-06-02 The Ohio State University Method for the stimulation of cell growth and the inhibition of cell proliferation by the utilization of selenodithiols such as selenodiglutathione
US5420011A (en) * 1993-04-12 1995-05-30 The United States Of America As Represented By The Department Of Health And Human Services Cell bioassay for neurotoxins

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
D.A.SCUDIERO ET AL.: "Evaluation of a Soluble Tetrazolium/Formazan Assay for Cell Growth and Drug Sensitivty in Culture Using Human and Other Tumour Cell Lines.", CANCER RESEARCH, vol. 48, no. 17, 1 September 1988 (1988-09-01), pages 4827 - 4833 *
J.F.JELLETT ET AL.: "Paralytic shellfish poison (saxitoxin family) bioassays: automated endpoint determination and standardization of the in vitro tissue culture bioassay, and comparison with the standard mouse bioassay.", TOXICON, vol. 30, no. 10, 1992, pages 1143 - 1156 *
K.D.PAULL ET AL.: "The Synthesis of XTT: A New Tetrazolium Reagent that is Bioreducible to a Water Soluble Formazan.", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 25, 1988, pages 911 - 913 *
K.KOGURE ET AL.: "A tissue culture assay for tetrodotoxin, saxitoxin and related toxins", TOXICON, vol. 26, no. 2, 1988, pages 191 - 197 *
R.L.MANGER ET AL.: "Tetrazolium-Based Cell Bioassay for Neurotoxins Active on Voltage-Sensitive Sodium Channels: Semiautomated Assay for Sagitoxins, Brevetoxins and Ciguatoxins.", ANALYTICAL CHEMISTRY, vol. 214, no. 1, 1 October 1993 (1993-10-01), pages 190 - 194 *
T.MOSMANN: "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity assays.", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 65, no. 1-2, 16 December 1983 (1983-12-16), pages 55 - 63 *

Also Published As

Publication number Publication date
AU6530894A (en) 1994-11-08
US5420011A (en) 1995-05-30
US6174690B1 (en) 2001-01-16
US5858687A (en) 1999-01-12

Similar Documents

Publication Publication Date Title
Manger et al. Tetrazolium-based cell bioassay for neurotoxins active on voltage-sensitive sodium channels: semiautomated assay for saxitoxins, brevetoxins, and ciguatoxins
US5420011A (en) Cell bioassay for neurotoxins
Vieytes et al. A fluorescent microplate assay for diarrheic shellfish toxins
Lewalter et al. Blood protein conjugates and acetylation of aromatic amines: new findings on biological monitoring
Sykes et al. Development of an Alamar Blue viability assay in 384-well format for high throughput whole cell screening of Trypanosoma brucei brucei bloodstream form strain 427
Riss Is your MTT assay really the best choice
Odds Antifungal susceptibility testing of Candida spp. by relative growth measurement at single concentrations of antifungal agents
Alexander et al. Evaluation of an adenosine 5'-triphosphate assay as a screening method to detect significant bacteriuria
Oh et al. Rapid viability assessment of yeast cells using vital staining with 2-NBDG, a fluorescent derivative of glucose
Ikehara et al. A protein phosphatase 2A (PP2A) inhibition assay using a recombinant enzyme for rapid detection of microcystins
CN102944550B (en) Detection kit for calcium peroxide in flour and detection method for calcium peroxide
Gülden et al. Comparison of mammalian and fish cell line cytotoxicity: impact of endpoint and exposure duration
EP0563114B1 (en) Diagnostic test
US5759860A (en) Automated analysis method for detecting bacterial nitrite in urine
Colombi et al. Low-pH method for the enzymatic assay of D-glucaric acid in urine
Volpe et al. A bienzyme electrochemical probe for flow injection analysis of okadaic acid based on protein phosphatase-2A inhibition: an optimization study
González et al. Inter-laboratory validation of the fluorescent protein phosphatase inhibition assay to determine diarrhetic shellfish toxins: intercomparison with liquid chromatography and mouse bioassay
Nicolau et al. Effect of different toxic compounds on ATP content and acid phosphatase activity in axenic cultures of Tetrahymena pyriformis
FI67404B (en) FOERFARANDE FOER UTFOERING AV MUTAGENITETTEST
Bank et al. Parameters for evaluation of viability assays: accuracy, precision, specificity, sensitivity, and standardization
Onyango et al. An automated biological assay to determine levels of the trypanocidal drug melarsoprol in biological fluids
Bishop et al. Quantitative assay for antibiotics used commonly in treatment of bovine infections
CN1414390A (en) Fipronil immune detecting method
Grovel et al. A new and rapid bioassay for the detection of gliotoxin and related epipolythiodioxopiperazines produced by fungi
FI97151C (en) Enzymatic method for the determination of lactam antibiotics

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB HU JP KP KR KZ LK LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SK UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA